FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...

Q4 2024 Earnings Call Transcript March 26, 2025 Journey Medical Corporation beats earnings expectations. Reported EPS is $0.08, expectations were $-0.22. Operator: Ladies and gentlemen, thank you for ...

And in November 2024, our licensed partner, Cutia Therapeutics, received regulatory approval to market Amzeeq in China, which triggered a $1 million milestone payment to Journey. Continuing the ...

2024 reflects a $1.0 million milestone payment pursuant to Journey’s license agreement with Cutia Therapeutics (HK) Limited (“Cutia”) that became payable to us upon Cutia receiving marketing ...

And in November 2024, our licensed partner, Cutia Therapeutics received regulatory approval to market Amzeeq in China, which triggered a $1 million milestone payment to Journey. Continuing the ...

Trailing total returns as of 03/04/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) ...

At close: 28 March at 4:08:08 pm GMT+8 ...

1 Day 2487 -2.68% DJIA 1.65% S&P Mid Cap 400 2.40% Health Care/Life Sciences -0.59% ...

Plus Therapeutics shares are trading higher by 244% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset. The ‘Trade of the Day ...